The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...
Opinion
A medical breakthrough saved millions of lives during COVID. Why are we turning our backs on it now?
The U.S. government is turning its back on a medical breakthrough that has saved millions of lives, halting $500 million in federal funding to develop new mRNA vaccines against potentially ...
Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a ...
Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...
The official opening will be headlined by Dr Nomalungelo Gina, Deputy Minister of Science, Technology and Innovation, who ...
Zacks Investment Research on MSN
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
Moderna MRNA is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate ...
The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...
Backed by fresh European financing, BioNTech’s Kigali facility is emerging as the cornerstone of Africa’s mRNA vaccine ...
By stimulating cancer cells to produce a molecule that activates a signaling pathway in nearby immune cells, MIT researchers ...
The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.
Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback